ExploreWatchlistsPricing
  1. US-listed companies
  2. Adaptimmune Therapeutics PLC
  3. Financials
  4. Capital expenditures

Adaptimmune Therapeutics PLC (ADAPY)

Market cap
$5.73M
P/E ratio
SummaryFinancials
Period EndCapital expenditures (Million USD)YoY (%)
Dec 31, 2024-1-81.07%
Dec 31, 2023-5-84.13%
Dec 31, 2022-29+244.02%
Dec 31, 2021-9+266.25%
Dec 31, 2020-2+47.05%
Dec 31, 2019-2-59.28%
Dec 31, 2018-4-84.13%
Dec 31, 2017-25+114.18%
Dec 31, 2016-12

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat